Association between A240T polymorphism and cancer risk: a meta-analysis.

OBJECTIVES

The relationship between the A240T polymorphism in the angiotensin-converting enzyme () gene and cancer risk remains controversial. Therefore, we conducted a meta-analysis of relevant studies from the published literature.

METHODS

We comprehensively searched available databases to identify eligible studies on the relationship of A240T polymorphism with cancer risk. We calculated pooled odds ratios (OR) with 95% confidence intervals (CI) and then evaluated heterogeneity and publication bias.

RESULTS

Eight case-control studies were identified from five articles. Results showed that the A240T polymorphism was related to cancer risk (AT vs AA: OR 2.14, 95% CI: 1.51–3.04; TT vs AA: OR 1.07, 95% CI: 0.90–1.27; recessive model: OR 0.48, 95% CI: 0.31–0.77; dominant model: OR 2.13, 95% CI: 1.54–2.97). The same conclusion was made for subgroup analysis by race or cancer type. In the subgroup analysis by quality score assessment, the A240T polymorphism contributed to cancer risk in high-quality studies but not in low-quality studies.

CONCLUSION

The A240T polymorphism in the gene might be related to the risk of cancer. Nevertheless, large-scale studies should be performed to obtain convincing evidence on the roles of A240T polymorphism on cancer risk.